In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1606-1608

  Levasseur, Premavathy ^a   Girard, Anne Marie ^a   Claudon, Monique ^a   Goossens, Herman ^b   Black, Michael T ^a   Coleman, Kenneth ^a   Miossec, Christine ^a  

^a Novexel SA   (France)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AZTREONAM; CEFTAZIDIME; CLAVULANIC ACID; IMIPENEM; PIPERACILLIN; SULBACTAM; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DNA RESTRICTION; DRUG POTENCY; HUMAN; HYDROLYSIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASES; CEFTAZIDIME; DRUG COMBINATIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84857173233     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06064-11     Document Type: Article

References (10)

1. Bonnefoy A, et al. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410-417. (Pubitemid 39177462)
2. Clinical Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first international supplement, vol 31, no 1. M100-S21. Clinical Laboratory Standards Institute, Wayne, PA.
3. Lister PD, Wolter DJ, Hanson ND. 2010. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610.
4. Mushtaq S, Warner M, Livermore DL. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other nonfermenters. J. Antimicrob. Chemother. 65:2376-2381.
5. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641.
6. Souli M, Galani I, Giamarellou H. 2008. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13:1-11.
7. Stachyra T, et al. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemases and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329.
8. Tam V, et al. 2010. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob. Agents Chemother. 54:3717-3722.
9. Tenover FC, et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
10. Walkty A, et al. 2011. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother. 55:2992-2994.